{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-22257418-liraglutide:v1","objectPathId":"pubmed-pmid-22257418-liraglutide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-22257418-liraglutide/","json":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-22257418-liraglutide-v1.json","markdown":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-22257418-liraglutide-v1.md"},"story":{"slug":"pubmed-pmid-22257418-liraglutide","version":1,"domain":"Literature metadata","dateInSource":"2015-11-19","sourceCheckedAt":"2026-07-30","publishedAt":"2026-08-13","peptideSlugs":["liraglutide"],"peptides":[{"slug":"liraglutide","url":"https://peptidescanner.com/peptides/liraglutide/"}]},"claims":[{"id":"headline","text":"Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy.","sourceIds":["pubmed-observation-pmid-22257418-2015-11-19-c9e08ae18400"]},{"id":"summary","text":"PubMed lists PMID 22257418 in Diabetes research and clinical practice as Case Reports, Letter, with publication-date metadata of 2012-01-16 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-22257418-2015-11-19-c9e08ae18400"]},{"id":"paragraph-1","text":"PubMed lists PMID 22257418 in Diabetes research and clinical practice as Case Reports, Letter, with publication-date metadata of 2012-01-16 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-22257418-2015-11-19-c9e08ae18400"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-22257418-2015-11-19-c9e08ae18400"]}],"sources":[{"id":"pubmed-observation-pmid-22257418-2015-11-19-c9e08ae18400","name":"PubMed","sourceClass":"A","title":"Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy. · retained source version 1:2015-11-19:current:c9e08ae18400076736e5728ca858ed27de28df2c784180ba210c9261903a801c","url":"https://pubmed.ncbi.nlm.nih.gov/22257418/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"d64dab24dfc10ba8e4126c820ee7fdba6955c73706ab05de8b44d7489ea0d717","tierARecordSha256":"897262b4843f66c1106f6d3a7229f057ffbbdacbd6cd2052aaf6479bc587071c"},"integrity":{"algorithm":"sha256","contentSha256":"5077aa6afc36172aa0f80083524c5ddcee4b14fef545a40a51a48e384f3935c6"}}